Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy.

IF 2.2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Esophagus Pub Date : 2023-10-01 Epub Date: 2023-04-24 DOI:10.1007/s10388-023-01006-y

Motoo Nomura, Taisuke Hosokai, Masashi Tamaoki, Akira Yokoyama, Shigemi Matsumoto, Manabu Muto

{"title":"Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy.","authors":"Motoo Nomura, Taisuke Hosokai, Masashi Tamaoki, Akira Yokoyama, Shigemi Matsumoto, Manabu Muto","doi":"10.1007/s10388-023-01006-y","DOIUrl":null,"url":null,"abstract":"Background: The immune system is affected by the circadian rhythm. The objective of this study was to clarify whether time-of-day patterns (early or late in the daytime) of the infusion of nivolumab and whether its duration affect treatment efficacy in metastatic or recurrent esophageal squamous cell carcinoma (R/M-ESCC).Methods: The data of 62 consecutive patients with R/M-ESCC treated with nivolumab between February 2017 and May 2022 were retrospectively reviewed. The infusion of nivolumab before 13:00 was set as 'early in the day', and that after 13:00 was set as 'late in the day'. The treatment efficacy was compared between early and late groups by 3 criteria (first infusion, during the first 3 months, and all treatment courses).Results: The overall survival, progression-free survival, and response rate of patients received the first dose in the early group were significantly superior to those of patients in the late group. The progression-free survival and response rate of patients who received the majority of nivolumab infusions before 13:00 during the first 3 months were significantly superior to those who received it after 13:00, with the exception of overall survival. There were no significant differences in the overall survival, progression-free survival, and response rate between patients who received the majority of nivolumab infusions before 13:00 of all treatment courses and those who received it after 13:00.Conclusion: The timing of the infusion of nivolumab may affect treatment efficacy in R/M-ESCC.","PeriodicalId":11918,"journal":{"name":"Esophagus","volume":"20 4","pages":"722-731"},"PeriodicalIF":2.2000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123478/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Esophagus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10388-023-01006-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: The immune system is affected by the circadian rhythm. The objective of this study was to clarify whether time-of-day patterns (early or late in the daytime) of the infusion of nivolumab and whether its duration affect treatment efficacy in metastatic or recurrent esophageal squamous cell carcinoma (R/M-ESCC).

Methods: The data of 62 consecutive patients with R/M-ESCC treated with nivolumab between February 2017 and May 2022 were retrospectively reviewed. The infusion of nivolumab before 13:00 was set as 'early in the day', and that after 13:00 was set as 'late in the day'. The treatment efficacy was compared between early and late groups by 3 criteria (first infusion, during the first 3 months, and all treatment courses).

Results: The overall survival, progression-free survival, and response rate of patients received the first dose in the early group were significantly superior to those of patients in the late group. The progression-free survival and response rate of patients who received the majority of nivolumab infusions before 13:00 during the first 3 months were significantly superior to those who received it after 13:00, with the exception of overall survival. There were no significant differences in the overall survival, progression-free survival, and response rate between patients who received the majority of nivolumab infusions before 13:00 of all treatment courses and those who received it after 13:00.

Conclusion: The timing of the infusion of nivolumab may affect treatment efficacy in R/M-ESCC.

Abstract Image

查看原文本刊更多论文

复发或转移性食管鳞状细胞癌患者输注nivolumab的时间影响其疗效。

背景：免疫系统受昼夜节律的影响。本研究的目的是明确nivolumab输注的时间模式（白天早或晚）及其持续时间是否会影响转移性或复发性食管鳞状细胞癌（R/M-ESCC）的治疗效果审查。在13:00之前输注nivolumab被设定为“当天早些时候”，在13:00之后输注nivoumab被设置为“当天晚些时候”。通过3个标准（首次输注、前3个月和所有疗程）比较早期组和晚期组的治疗效果。结果：早期组接受第一剂治疗的患者的总生存率、无进展生存率和有效率显著优于晚期组。在前3个月13:00之前接受大多数nivolumab输注的患者的无进展生存率和有效率显著高于13:00之后接受的患者，但总生存率除外。在所有疗程的13:00之前接受大部分nivolumab输注的患者与13:00之后接受的患者在总生存率、无进展生存率和有效率方面没有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Esophagus GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

4.90

自引率

8.30%

发文量

审稿时长

>12 weeks

期刊介绍： Esophagus, the official journal of the Japan Esophageal Society, introduces practitioners and researchers to significant studies in the fields of benign and malignant diseases of the esophagus. The journal welcomes original articles, review articles, and short articles including technical notes ( How I do it ), which will be peer-reviewed by the editorial board. Letters to the editor are also welcome. Special articles on esophageal diseases will be provided by the editorial board, and proceedings of symposia and workshops will be included in special issues for the Annual Congress of the Society.